#USA #New York #Google Cloud #Clinical AI #MAIA™

Clinical AI Launches MAIA™ Prescreening on Google Cloud Marketplace

Clinical AI, a pioneering healthcare artificial intelligence company, has announced the introduction of MAIA™ Prescreening on Google Cloud Marketplace. This innovative solution aims to revolutionize clinical trial operations by enhancing patient screening processes, expanding access to trials, and ultimately accelerating the timelines to life-saving treatments.

The Challenge of Clinical Trials

Clinical trial enrollment represents a significant hurdle in medical research, affecting approximately 80% of studies due to protocol complexities and the necessity for extensive manual patient screenings. Research sites frequently find themselves screening thousands of patients, resulting in prolonged trial timelines and heightened operational costs. MAIA™ has been developed specifically to tackle these challenges through its advanced automation capabilities.

Transformative Features of MAIA™

MAIA™ utilizes the power of Google’s Gemini models, allowing healthcare organizations to deploy AI-driven patient screening workflows directly. According to Dai Vu, a Managing Director at Google Cloud, the integration of Clinical AI's solutions within its trusted infrastructure will enable healthcare professionals to securely scale their operations and enhance patient engagement efficiently.

Hamza Hasan, CEO of Clinical AI, emphasized how MAIA™ is designed to not only lighten the workload for research teams but also to significantly boost the speed and efficiency of patient screenings across numerous trials. With MAIA™ available on Google Cloud Marketplace, the technology is now more accessible than ever, aiming to enhance participation in clinical trials globally.

Proven Success in Real-World Applications

In a real-world oncology study, MAIA™ allowed a clinical trial site to double its screening capabilities, addressing 500 patients per month instead of only 250. This crucial advancement resulted in an impressive 80% increase in trial enrollment, generating an estimated additional $5 million in annual revenue for the site. The prescreening accuracy delivered by MAIA™ consistently exceeds 95%, making it a trusted solution across various therapeutic areas.

Comprehensive Workflow Support

Beyond prescreening capabilities, MAIA™ extends its functions to support a range of clinical trial workflows:

• - Interactive Virtual Assistants: These assist with patient and site engagement leveraging AI-based guidance informed by trial-specific documents.
• - Trial Simulations: These enable sponsors and sites to assess patient populations and fine-tune eligibility criteria before trials commence.
• - Financial Document Management: Streamlining budget evaluations and development of trial-related financial documents to enhance operational efficiency.
• - Multilingual Document Processing: Facilitating language translation and backtranslation to support diverse, multilingual clinical trials.
• - Comprehensive Lab Information Management: Offering a holistic tracking system from sample collection through testing.

By offering MAIA™ on Google Cloud Marketplace, Clinical AI is making it easier for healthcare organizations to integrate this powerful tool into secure clinical environments. This system not only enhances screening capabilities across various trials and locations but also shapes the future of clinical research approaches.

Availability And Future Prospects

MAIA™ Prescreening is now fully available on Google Cloud Marketplace. Organizations interested in leveraging this technology for improved clinical trial operations can learn more by visiting www.clinicalai.us or reaching out via email at [email protected].

About Clinical AI

Founded with the goal of optimizing clinical trial execution, Clinical AI focuses on developing artificial intelligence solutions that enhance operational efficiency and accelerate the patient recruitment process. Its flagship platform, MAIA™, is at the forefront of this initiative, helping research teams connect eligible patients to clinical trials more effectively than ever before.